Key Messages to Investors
Please read our caution about Forward-Looking Statements in the Conditions of Use when using this information.
- Creating a global leader in agriculture through acquisition of Monsanto*
- Proven integration/separation capabilities
- Track record of delivering shareholder value through successful portfolio management
- Mid-term aspirations emphasize growth and margin potential
- Pharma launch products expected to drive growth; peak sales potential increased
to >€10bn - Consumer health challenges addressed
- Crop Science expected to benefit from cyclical market upswing and long-term
GDP+ growth potential
- Upcoming new product launches and life cycle management at Pharma expected to mitigate loss of exclusivity post 2023
- Combined peak sales potential of key late-stage Pharma pipeline assets ≥€6bn
- Consumer Health delivering steady stream of consumer-centric innovations
- Strong R&D capabilities at combined Crop Science business*
* Acquisition of Monsanto pending